Journal
BLOOD REVIEWS
Volume 31, Issue 5, Pages 318-327Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2017.05.002
Keywords
Obinutuzumab; Ocaratuzumab; Ofatumumab; Rituximab; Ublituximab; Veltuzumab
Categories
Ask authors/readers for more resources
The anti-CD20 antibodies represent a major advancement in the therapeutic options available for chronic lymphocytic leukemia. The addition of rituximab, ofatumumab and obinutuzumab to various chemotherapy regimens has led to considerable improvements in both response and survival. Ocaraturtimab, veltuzumab and ublituximab are currently being explored within the trial setting. We review the current status of these antibodies, and discuss how their mechanisms of action may impact on the choice of combinations with novel small molecule agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available